Ellen Rosenberg Biography and Net Worth

Insider of Amicus Therapeutics

Ellen S. Rosenberg J.D. serves as General Counsel, Corporate Secretary, Chief Legal Officer of the Company. Prior to joining Amicus, she served as a Senior Vice President of Shire Pharmaceuticals. Prior to Shire, Ms. Rosenberg was Associate General Counsel for the Metabolic Endocrinology division at EMD Serono Inc., the U.S. affiliate of Merck KGaA. Ms. Rosenberg brings extensive and broad ranging legal experience in the biopharmaceutical and medical device industry including mergers and acquisitions, licensing, corporate governance, product launches, risk management, litigation, investigations and compliance matters. Ms. Rosenberg also has significant experience building and developing legal teams and the in-house legal function. Ms. Rosenberg received a B.A. from the University of Connecticut and a J.D. from the University of Pennsylvania Law School.

What is Ellen Rosenberg's net worth?: The estimated net worth of Ellen Rosenberg is at least $3.60 million as of February 6th, 2024. Ms. Rosenberg owns 367,654 shares of Amicus Therapeutics stock worth more than $3,603,009 as of December 21st. This net worth estimate does not reflect any other investments that Ms. Rosenberg may own. Additionally, Ms. Rosenberg receives an annual salary of $733,940.00 as Insider at Amicus Therapeutics. Learn More about Ellen Rosenberg's net worth.
How old is Ellen Rosenberg?: Ms. Rosenberg is currently 61 years old. There are 5 older executives and no younger executives at Amicus Therapeutics. The oldest executive at Amicus Therapeutics is Mr. Simon Nicolas Reade Harford, Chief Financial Officer, who is 64 years old. Learn More on Ellen Rosenberg's age.
What is Ellen Rosenberg's salary?: As the Insider of Amicus Therapeutics, Inc., Ms. Rosenberg earns $733,940.00 per year. The highest earning executive at Amicus Therapeutics is Mr. Bradley L. Campbell M.B.A., CEO, President & Director, who commands a salary of $984,090.00 per year. Learn More on Ellen Rosenberg's salary.
How do I contact Ellen Rosenberg?: The corporate mailing address for Ms. Rosenberg and other Amicus Therapeutics executives is 1 Cedar Brook Drive, Cranbury NJ, 08512. Amicus Therapeutics can also be reached via phone at (215) 921-7600 and via email at [email protected]. Learn More on Ellen Rosenberg's contact information.
Has Ellen Rosenberg been buying or selling shares of Amicus Therapeutics?: Ellen Rosenberg has not been actively trading shares of Amicus Therapeutics during the last quarter. Most recently, Ellen Rosenberg sold 400 shares of the business's stock in a transaction on Tuesday, February 6th. The shares were sold at an average price of $13.00, for a transaction totalling $5,200.00. Following the completion of the sale, the insider now directly owns 367,654 shares of the company's stock, valued at $4,779,502. Learn More on Ellen Rosenberg's trading history.
Who are Amicus Therapeutics' active insiders?: Amicus Therapeutics' insider roster includes Lynn Bleil (Director), Bradley Campbell (CEO), Bradley Campbell (CEO), Jeff Castelli (Insider), David Clark (Insider), John Crowley (Chairman Emeritus), Margaret Mcglynn (Director), Samantha Prout (Insider), Michael Raab (Director), Ellen Rosenberg (Insider), Ellen Rosenberg (Insider), and Burke Whitman (Director). Learn More on Amicus Therapeutics' active insiders.
Are insiders buying or selling shares of Amicus Therapeutics?: During the last year, insiders at the biopharmaceutical company sold shares 22 times. They sold a total of 316,307 shares worth more than $4,102,561.17. The most recent insider tranaction occured on December, 2nd when CEO Bradley L Campbell sold 7,500 shares worth more than $75,150.00. Insiders at Amicus Therapeutics own 2.2% of the company. Learn More about insider trades at Amicus Therapeutics.
Information on this page was last updated on 12/2/2024.

Ellen Rosenberg Insider Trading History at Amicus Therapeutics

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
2/6/2024	Sell	400	$13.00	$5,200.00	367,654
1/2/2024	Sell	30,000	$14.21	$426,300.00	342,285
12/27/2023	Sell	5,000	$14.07	$70,350.00	342,285
1/24/2023	Sell	31,839	$13.32	$424,095.48	332,345
8/1/2022	Sell	11,123	$10.02	$111,452.46	280,707
6/21/2022	Sell	11,122	$10.00	$111,220.00	291,830
4/7/2022	Sell	11,018	$9.06	$99,823.08	302,952
7/16/2020	Sell	30,000	$15.26	$457,800.00	225,169
1/15/2020	Sell	22,100	$10.35	$228,735.00	185,350
6/2/2016	Buy	15,000	$7.67	$115,050.00

Ellen Rosenberg Buying and Selling Activity at Amicus Therapeutics

Amicus Therapeutics Company Overview

Amicus Therapeutics, Inc., a biotechnology company, focuses on discovering, developing, and delivering medicines for rare diseases. Its commercial product and product candidates include Galafold, an oral precision medicine for the treatment of adults with a confirmed diagnosis of Fabry disease and an amenable galactosidase alpha gene variant; and Pombiliti + Opfolda, for the treatment of late onset. It has collaboration and license agreements with the University of Pennsylvania to research and develop parvovirus gene therapy products; and GlaxoSmithKline. Amicus Therapeutics, Inc. was incorporated in 2002 and is headquartered in Princeton, New Jersey.

Today's Range

Now: $9.80

$9.60

$9.88

50 Day Range

MA: $10.48

$9.36

$12.01

2 Week Range

Now: $9.80

$9.02

$14.57

Volume

4,077,524 shs

Average Volume

2,724,375 shs

Market Capitalization

$2.93 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.6

Media Humiliated: Demo of Elon’s Tech Proves They’re Wrong

From Brownstone Research | Ad

Elon Musk believes his new AI product will be worth an incredible $9 trillion. But the mainstream media is not buying it.

Click here to watch this demo and decide for yourself.

Ellen Rosenberg Biography and Net Worth

What is Ellen Rosenberg's net worth?

How old is Ellen Rosenberg?

What is Ellen Rosenberg's salary?

How do I contact Ellen Rosenberg?

Has Ellen Rosenberg been buying or selling shares of Amicus Therapeutics?

Who are Amicus Therapeutics' active insiders?

Are insiders buying or selling shares of Amicus Therapeutics?